Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. (Q34409128)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

main subject

hepatocellular carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Robert S Brown

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Abby B Siegel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic Advances in Gastroenterology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

55-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

18 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Molecular profiling to predict hepatocellular carcinoma outcome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Long-term results after liver transplantation with "livers that nobody wants" within Eurotransplant: a center's experience

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Pivotal role of mTOR signaling in hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Molecular targeted therapies in hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Sirolimus therapy in liver transplant patients: an initial experience at a single center.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Sorafenib in advanced hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Design and endpoints of clinical trials in hepatocellular carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Transcription factors control invasion: AP-1 the first among equals

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

New aspects of diagnosis and therapy of hepatocellular carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Management of hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Updated treatment approach to hepatocellular carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Chemoembolization for hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Selection of candidates with HCC for transplantation in the MELD era.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Randomized controlled trial of screening for hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

6 July 2018

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Prognosis of hepatocellular carcinoma: the BCLC staging classification

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

University of California at San Francisco criteria can be applied to living donor liver transplantation for hepatocellular carcinoma: single-center preliminary results in 27 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

Living donor liver transplantation for hepatocellular carcinoma: a single centre experience.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002567

HCC surveillance: Who is the target population?

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

Epidemiology of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X09346669

A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma

1 reference

12 December 2020

Estimates of the world-wide prevalence of cancer for 25 sites in the adult population

1 reference

12 December 2020

Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver

1 reference

12 December 2020

Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells

1 reference

12 December 2020

Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations

1 reference

12 December 2020

Rising incidence of hepatocellular carcinoma in the United States

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X09346669

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21180590%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference